BlackRock Amends Aclaris Therapeutics Stake, Remains Passive Investor
Ticker: ACRS · Form: SC 13G/A · Filed: Jan 25, 2024 · CIK: 1557746
| Field | Detail |
|---|---|
| Company | Aclaris Therapeutics, INC. (ACRS) |
| Form Type | SC 13G/A |
| Filed Date | Jan 25, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**BlackRock still owns Aclaris stock, but they're not trying to run the show.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 25, 2024, disclosing its ownership in Aclaris Therapeutics, Inc. as of December 31, 2023. This filing, an amendment to a previous disclosure, indicates BlackRock's continued significant, but passive, investment in Aclaris. For investors, this means a major institutional player maintains a stake, which can signal confidence, but the 'passive' nature means BlackRock isn't looking to influence company management.
Why It Matters
This filing confirms BlackRock, a major institutional investor, continues to hold a significant position in Aclaris Therapeutics, Inc., providing a degree of institutional validation for current and prospective shareholders.
Risk Assessment
Risk Level: low — This filing is routine and indicates a stable, passive institutional investment, posing minimal immediate risk to shareholders.
Analyst Insight
Investors should note BlackRock's continued passive stake in Aclaris Therapeutics, Inc., which suggests institutional confidence without any indication of activist intent. This information can be factored into a broader analysis of the stock's institutional ownership and stability.
Key Players & Entities
- BlackRock Inc. (company) — the reporting person and institutional investor
- Aclaris Therapeutics, Inc. (company) — the subject company in which BlackRock holds shares
- December 31, 2023 (date) — the date of the event requiring the filing
- January 25, 2024 (date) — the filing date of the SC 13G/A amendment
Forward-Looking Statements
- BlackRock will maintain a passive investment strategy in Aclaris Therapeutics, Inc. (BlackRock Inc.) — high confidence, target: December 31, 2024
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, as indicated by 'FORM TYPE: SC 13G/A' and '(Amendment No: 2)' in the filing.
Who is the reporting person in this filing?
The reporting person is BlackRock, Inc., as stated under '(1)Names of reporting persons. BlackRock, Inc.' in the filing.
What is the subject company of this filing?
The subject company is Aclaris Therapeutics, Inc., as identified under 'Name of Issuer) Aclaris Therapeutics, Inc.' in the filing.
What was the date of the event that required this filing?
The date of the event which required this filing was December 31, 2023, as stated under '(Date of Event Which Requires Filing of this Statement) December 31, 2023'.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13d-1(b), indicated by '[X] Rule 13d-1(b)' in the filing.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 25, 2024 regarding Aclaris Therapeutics, Inc. (ACRS).